GP 2a
Biological Activity
Selective CB2 receptor agonist; Ki values are 7.6 and 900 nM for CB2 and CB1 receptors respectively. Increases P-ERK1/2 expression in HL-60 cells in vitro.
Technical Data
| M. Wt | 440.36 |
| Formula | C24H23Cl2N3O |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 919077-81-9 |
| PubChem ID | 16094766 |
| InChI Key | SPEFJYZGXZENAF-UHFFFAOYSA-N |
| Smiles | CC1=CC=C2C(CC3=C2N(N=C3C(=O)NC2CCCCC2)C2=CC=C(Cl)C=C2Cl)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 22.02 | 50 | |
| ethanol | 8.81 | 20 |
Preparing Stock Solutions
The following data is based on the product molecular weight 440.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.54 mL | 22.71 mL | 45.42 mL |
| 2.5 mM | 0.91 mL | 4.54 mL | 9.08 mL |
| 5 mM | 0.45 mL | 2.27 mL | 4.54 mL |
| 25 mM | 0.09 mL | 0.45 mL | 0.91 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Murineddu et al (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxam J.Med.Chem. 49 7502 PMID: 17149879
If you know of a relevant reference for GP 2a, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GP 2a, GP 2a supplier, Selective, CB2, agonists, cannabinoids, Receptors, GP2a, cb2r, 2678, Tocris Bioscience
Citations for GP 2a
Citations are publications that use Tocris products.
Currently there are no citations for GP 2a. Do you know of a great paper that uses GP 2a from Tocris? Please let us know.
Reviews for GP 2a
There are currently no reviews for this product. Be the first to review GP 2a and earn rewards!
Have you used GP 2a?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Cannabinoid Receptor Ligands Scientific Review
Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.
Epilepsy PosterNew
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
